Suzhou Chung-Hwa Pharmaceutical Industrial Co., Ltd. (hereinafter referred to as "Suzhou Chung-Hwa Chemical & Pharmaceutical") was established in 1993. Its Yong'an Road Site was officially put into operation in 2014, located in Suzhou National New & High-Tech Industrial Development Zone. It is the first Taiwan-invested pharmaceutical enterprise to enter the Chinese mainland market, with investment from Taiwan-based Cenra Inc. The company integrates research and development, manufacturing, and sales. As a national high-tech enterprise, it not only ranks among the first batch of GMP-certified companies in China but also has obtained Japanese PMDA certification for its high-quality production standards, establishing a dual quality management system that integrates both domestic and international standards.

Suzhou Chung-Hwa Chemical & Pharmaceutical has established a Cross-Strait Joint Research Institute in collaboration with the Cenra Inc. Research Institute. Leveraging R&D resources from both sides of the strait, and adhering to cutting-edge pharmaceutical concepts and a technology-driven innovation approach, the company has built core technological advantages. It operates a GMP compliant pilot formulation workshop and has put in place an international quality management system covering the full lifecycle of pharmaceutical products. From supplier audit and raw & auxiliary material procurement, to production process control and finished product release, scientific and standardized management procedures ensure full system quality compliance at every stage. Through stringent quality control, we uphold our core commitment to patient medication safety.

The company has achieved strategic layout and in depth coverage across the national market, holding over 100 drug production approvals and more than 40 patent certificates, and has established a diversified product portfolio. Its current major drug categories include medications for the digestive system, cardiovascular system, endocrine system, musculoskeletal system, anti-infective drugs, and several other therapeutic areas.

Suzhou Chung-Hwa Chemical & Pharmaceutical's CDMO division focuses on R&D and manufacturing of lab scale batches, pilot batches, validation batches and commercial scale batches for pharmaceutical products. Drawing on over 30 years of heritage and accumulated pharmaceutical expertise, it has forged core strengths featuring robust systems, full regulatory compliance, and balanced quality cost performance. Upholding customer centricity and quality first service principles, it is committed to providing customers with professional customized R&D and manufacturing services for pharmaceutical formulations.

Suzhou Chung-Hwa Chemical & Pharmaceutical boasts nearly 20 years of domestic and overseas contract manufacturing experience. It has established partnerships with more than 20 customers worldwide, covering entrusted registration & approval, contract manufacturing and export sales. The business scope includes over 40 product specifications, Its business footprint spans Chinese mainland, Hong Kong, as well as Japan, the Philippines, Vietnam, Myanmar, African countries and other regions.

Suzhou Chung-Hwa Chemical & Pharmaceutical consistently upholds its vision of “Empowering health equity, propelling a healthier world for all”. It advocates its core values: “Human-centric Innovation, Pursuit of Excellence, Agility, Integrity”. We are committed to providing high-quality and wide-ranging healthcare solutions that address diverse needs of individuals worldwide, paving the path towards a healthier future for all.

About Cenra lnc.

Founded in 1952 as China Chemical & Pharmaceutical, Cenra has grown from a pioneering pharmaceutical company into a diversified healthcare platform. With over 70 years of experience, Its affiliated enterprises include Cenra + Pharma, Cenra + Healthcare, Cenra + Senior Care, and Cenra + API Solutions, among others. we deliver high-quality medicines, consumer health products, and care services across every stage of life. Through innovation, trusted execution, and long-term partnerships, we are building a modern healthcare platform that meets the evolving needs of patients, providers, and partners across Asia and beyond.